mRNA encoding methylmalonyl-CoA mutase for metabolic disorder treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for methylmalonic acidemia (MMA), including dietary control and kidney and liver transplants, are inadequate in completely or reliably controlling the disorder.
Innovation Solution
A composition comprising a polynucleotide encoding a methylmalonyl-CoA mutase (MCM) polypeptide combined with a delivery agent, specifically a compound of Formula (II) or its salt/isomer, is used to treat MMA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary control is used to limit metabolic pathways, then methylmalonic acid formation is reduced, but the treatment does not completely control the disorder
Solution Approach 1:
The patent uses a delivery agent (lipid nanoparticle or similar carrier system) as an intermediary to deliver the polynucleotide encoding MCM enzyme to target cells. This mediator enables the therapeutic polynucleotide to cross cell membranes and reach the mitochondrial compartment where MCM functions, thereby restoring metabolic capability without requiring complete dietary restriction.
2Reliability
If kidney and liver transplants are performed to provide new cells, then metabolic function is improved, but the treatment is not completely reliable and requires complex surgical intervention
Solution Approach 1:
The patent extracts only the essential functional element (the MCM enzyme-encoding polynucleotide) from the complex organ transplant procedure. Instead of transplanting entire kidneys or livers, the invention delivers just the genetic instructions for MCM production directly to cells, achieving the metabolic correction with a much simpler, less invasive approach.
Solution Approach 2:
The patent creates a copy of the functional MCM enzyme by delivering its genetic blueprint (polynucleotide) to patient cells. These cells then produce endogenous MCM enzyme, effectively copying the missing metabolic function without requiring transplantation of donor organs. This molecular copying approach avoids the complexities of organ matching, surgery, and immunosuppression.
3Reliability
If polynucleotide therapy is used to restore MCM function, then complete metabolic control is achieved, but delivery to target cells becomes the critical challenge
Solution Approach 1:
The patent employs a delivery agent as an intermediary carrier system that protects the polynucleotide from degradation, facilitates cellular uptake, and directs the therapeutic to the appropriate subcellular compartment. This mediator overcomes the natural barriers to polynucleotide delivery, including extracellular nucleases, cell membrane permeability, and mitochondrial import mechanisms.
Data Source
Figure 1
Figure 2A~2C
Figure 3
AI summary
The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.